The histopathologic and clinical features of 3 breast angiosarcomas were presented. The microscopic patterns were heterogeneous, comprising vascular structures in various degrees of differentiation and solid cellular proliferations, the proportion of which varied from tumor to tumor. All 3 tumors were classified in the third group of angiosarcomas. One widely-excised tumor recurred and developed lung metastases 11 months after mastectomy and during a polychemotherapy. The other 2 patients were well and free from disease 9/11 months after the surgical and radiation therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1699-0463.1987.tb00049_95a.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiomics characterization of breast angiosarcoma from an Asian cohort reveals enrichment for angiogenesis signaling pathway and tumor-infiltrating macrophages.
Front Immunol
January 2025
Cancer Discovery Hub, National Cancer Centre Singapore, Singapore, Singapore.
Introduction: Recent epidemiological data suggests a rising incidence of breast angiosarcoma (AS-B) in the Western population, with over two-thirds related to irradiation or chronic lymphedema. However, unlike head and neck angiosarcoma (AS-HN), AS-B disease characteristics in Asia remain unclear.
Methods: We examined clinical patterns of angiosarcoma patients (n = 176) seen in an Asiantertiary cancer center from 1999 to 2021, and specifically investigated the molecular and immune features of AS-B in comparison to AS-HN.
A Rare Case of Primary Chondrosarcoma of the Breast: A Case Report and Comprehensive Literature Review.
Discoveries (Craiova)
September 2024
Department of Oncopathology, Homi Bhabha Cancer Hospital (HBCH) and Mahamana Pandit Madan Mohan Malviya Cancer Centre (MPMMCC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Varanasi, India.
Breast sarcomas are a diverse group of malignant neoplasms originating from the mammary stroma. They are uncommon tumors, often occurring as a component of other tumors. Among malignant breast mesenchymal tumors, pure sarcomas lacking epithelial components are even rarer, comprising only 0.
View Article and Find Full Text PDFNew Germline TP53 Variant Detected After Radiotherapy-Induced Angiosarcoma of the Chest Wall in a Previously Treated Breast Cancer Patient: A Case Report and Review of Li-Fraumeni Syndrome and Radiotherapy-Induced Sarcoma.
Case Rep Oncol Med
December 2024
Pathology Department, Oncoclinicas Group, São Paulo, Brazil.
Li-Fraumeni syndrome (LFS) is one of the most common hereditary cancer predisposition syndromes in Brazil. The high frequency of the syndrome is due to a founding variant (R337H) in the country. LFS is characterized by a wide variety of malignant phenotypes.
View Article and Find Full Text PDFCase of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient.
Acta Med Okayama
December 2024
Department of Radiology, Kawasaki Medical School.
Radiation-induced angiosarcoma (RIAS) is a rare, late adverse event of radiotherapy comprising approximately half of all radiation-induced sarcomas. It has a relatively short latency period and generally unfavorable prognosis. This study presents a case of RIAS that developed 5 years and 11 months after the completion of hypofractionated radiotherapy (42.
View Article and Find Full Text PDFDesign, Synthesis, and Evaluation of Trihalomethyl Ketone Derivatives of Neocarzilin A as Improved Antimetastatic Agents.
ACS Bio Med Chem Au
December 2024
Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, United States.
Vesicle Amine Transport-1 (VAT1) is a protein that is overexpressed in many cancers, including breast cancer, glioblastoma, and angiosarcoma. High VAT1 expression correlates with poor overall survival, and genetic knockout models of VAT1 indicate potent antimigratory activity, suggesting that VAT1 is a promising antimetastasis target. Recently, the natural product neocarzilin A (NCA) from was reported to be the first validated small-molecule inhibitor of VAT1, having strong activity in metastasis models of angiosarcoma and breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!